Skip to main content
Donate

FAST Announces Funding For First Innovative Seed Grant

FAST is excited to announce funding for its first Innovative Seed Grant, entitled “Hematopoietic stem cell mobilization, engineering, and engraftment without myeloablative conditioning”, awarded to Dr. Rachel Cunningham and Dr. Jennifer Adair. Dr. Adair is a Professor and Vice Chair in the Department of Genetic & Cellular Medicine at the University of Massachusetts, developing innovative, globally accessible treatments that engineer blood stem cells to combat genetic disorders, HIV, and cancers.

This grant is part of FAST’s commitment to Pillar 1, which aims to replace the missing or non-functional maternal copy of the UBE3A gene or protein in neurons of the brain. The Innovation Seed Grant program is designed to spark bold, groundbreaking research in Angelman syndrome by supporting high-risk, high-reward ideas that have the potential to transform both understanding and treatment of the disorder.

This project focuses on improving an approach that utilizes a patient’s own blood-forming stem cells (hematopoietic stem cells, or HSCs), which are modified outside the body to correct the genetic defect and then reinfused. Researchers will first test combinations of stem cell mobilization agents to identify the most effective and rapid way to isolate a high number of HSCs. Then, they will track these cells to ensure that these specialized cells, called microglia, are making it to the brain. Current HSC gene therapies require chemotherapy-based conditioning and complex and multi-day hospital stays that carry risks like immune suppression and are inaccessible to some patients.

If the experiments funded by the ISG are successful, this strategy could eliminate major barriers to current HSC therapy and lay the foundation for a next-generation, accessible treatment approach.

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.